Journal article

Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster

FM Russell, JR Carapetis, C Satzke, L Tikoduadua, L Waqatakirewa, R Chandra, A Seduadua, S Oftadeh, YB Cheung, GL Gilbert, EK Mulholland

Clinical and Vaccine Immunology | AMER SOC MICROBIOLOGY | Published : 2010

Abstract

This study was conducted to evaluate the effect of a reduced-dose 7-valent pneumococcal conjugate vaccine (PCV) primary series followed by a 23-valent pneumococcal polysaccharide vaccine (23vPPS) booster on nasopharyngeal (NP) pneumococcal carriage. For this purpose, Fijian infants aged 6 weeks were randomized to receive 0, 1, 2, or 3 PCV doses. Within each group, half received 23vPPS at 12 months. NP swabs were taken at 6, 9, 12, and 17 months and were cultured for Streptococcus pneumoniae. Isolates were serotyped by multiplex PCR and a reverse line blot assay. There were no significant differences in PCV vaccine type (VT) carriage between the 3- and 2-dose groups at 12 months. NP VT carria..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Institute of Allergy and Infectious Diseases


Funding Acknowledgements

Funding was provided by NIAID (grant R01 AI 52337) and the National Health and Medical Research Council. Pneumovax was kindly donated by CSL Biotherapies, Australia. The coadministered Tritanrix-HepB and Hiberix vaccines were kindly donated by GlaxoSmithKline.